Stocks
Guardant Health, Inc.

Guardant Health, Inc.GH

NASDAQHealthcareBiotechnology$156.84+1.75%

Price as of · delayed, not real-time

A precision oncology company focused on blood-based cancer diagnostics, Guardant Health develops liquid biopsy tests for early detection and treatment selection. Its flagship Guardant360 test analyzes circulating tumor DNA to guide therapy decisions, positioning it as a key player in the growing liquid biopsy market. Investors monitor its commercial adoption and pipeline progress in competing with tissue biopsy standards.

Market Cap: $11.2B52W Range: $53.40-$176.58

Congressional Interest in Guardant Health, Inc. (GH)

4 members of Congress have disclosed 14 trades in Guardant Health, Inc. (GH), a Healthcare company. The buy/sell breakdown shows 7 purchases versus 7 sales. All data is sourced from STOCK Act periodic transaction reports filed with Congress.

Total Disclosures
14
Unique Politicians
4
Buys
7
Sells
7

Who in Congress Is Trading GH?

2025-11-21$1K-$15K
Stock
2022-06-03$1K-$15K
Stock
2022-02-28$1K-$15K
Stock
2022-01-13$1K-$15K
Stock
2021-12-22$1K-$15K
Stock
2020-12-28$1K-$15K
Stock
2020-11-02$1K-$15K
Stock
2020-10-22$1K-$15K
Stock
2020-10-05$1K-$15K
Stock
2020-07-14$1K-$15K
Stock
2020-05-01$1K-$15K
Stock
2020-04-27$1K-$15K
Stock
2020-02-14$1K-$15K
Stock
2020-01-06$1K-$15K
Stock